FEIBA
Generic: ANTI-INHIBITOR COAGULANT COMPLEX
Basic Information
Manufacturer
Takeda Pharmaceuticals America, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
FDA Set ID
752604e5-4ea2-44f4-83ed-1569373f6412
Indications & Usage
1 INDICATIONS AND USAGE FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes.
Perioperative management.
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX.
( 1 )
FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes.
Perioperative management.
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX.
( 1 )
Adverse Reactions
6 ADVERSE REACTIONS The most frequently reported adverse reactions observed in >5% of subjects in the prophylaxis trial were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting.
The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
The most common adverse reactions observed in >5% of subjects were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting.
( 6.1 ) The serious adverse drug reactions are hypersensitivity and thromboembolic events, including stroke, pulmonary embolism, and deep vein thrombosis.
( 5.1 , 5.2 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc.
at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety assessment of FEIBA is based on the review of the data from two prospective clinical trials in which FEIBA was used for the treatment of acute bleeding episodes and a prospective trial that compared the use of FEIBA prophylactically versus on-demand treatment.
The adverse reactions reported from two prospective clinical trials in which FEIBA was used for the treatment of acute bleeding episodes were chills, chest pain, chest discomfort, dizziness, dysgeusia, dyspnea, hypoesthesia, increase of inhibitor titer (anamnestic response), nausea, pyrexia, and somnolence.
Specifically, the first trial was a multicenter randomized, double-blind trial in 15 hemophilia A subjects with inhibitors to factors VIII.
The second trial was a multicenter FEIBA study conducted in 44 hemophilia A subjects with inhibitors, 3 hemophilia B subjects with inhibitors and 2 acquired factor VIII inhibitor subjects.
Of the 489 infusions used to treat acute bleeds during the second trial, 18 (3.7%) caused minor transient reactions of chills, fever, nausea, dizziness and dysgeusia.
Out of 49 subjects, 10 (20%) had a rise in their inhibitor titers after treatment with FEIBA.
Five of these subjects (50%) had increases that were tenfold or more, and 3 (30%) of these subjects received factor VIII or IX concentrates within 2 weeks prior to treatment with FEIBA.
These anamnestic rises were not associated with decreased efficacy of FEIBA.
Table 2 lists the adverse reactions in >5% of subjects reported in the randomized, prospective prophylaxis trial comparing FEIBA prophylaxis with on-demand treatment in 36 hemophilia A and B subjects with inhibitors to factors VIII or IX 3 .
The trial population included 33 (92%) subjects with hemophilia A and 3 (8.3%) subjects with hemophilia B.
Four (11%) subjects were ≥7 to <12 years of age, 5 (14%) were ≥12 to <16 years of age, and 27 (75%) were ≥16 years of age.
A total of 29 (80.6%) subjects were Caucasian, 3 (8.3%) Asian, 2 (5.6%) Black/African American, and 2 (5.6%) other.
The subjects received a total of 4,513 infusions (3,131 for prophylaxis and 1,382 for on-demand).
Table 2: Prophylaxis Study Adverse Reactions (ARs) in >5% of Subjects MedDRA System Organ Class Adverse Reaction Number of ARs Number of Subjects Percent of Subjects (N=36) Blood And Lymphatic System Disorders Anemia 2 2 5.6 Gastrointestinal Disorders Diarrhea 2 2 5.6 Nausea 2 2 5.6 Vomiting 2 2 5.6 Investigations Hepatitis B Surface Antibody Positive 4 4 11.1 Musculoskeletal And Connective Tissue Disorders Hemarthrosis 5 3 8.3 Table 3 lists the adverse reactions and infusion related adverse events reported in >5% of subjects in any of the three groups (50% Reduced Volume, Increased Rate 4 U/kg/min; 50% Reduced Volume, Increased Rate 10 U/kg/min; Overall 50% Reduced Volume) of the randomized, prospective crossover trial evaluating the tolerability and safety of infusing reduced volume of FEIBA at the standard infusion rate of 2 U/kg/min, and at increased rates of 4 and 10 U/kg/min in a total of 33 treated subjects with congenital Hemophilia A with inhibitors.
Table 3: Adverse Reactions (ARs) and Infusion Related Adverse Events in >5% of Subjects, in Patients 18 Years and Older MedDRA System Organ Class Adverse Reaction 50% Reduced Volume; Increased Rate 4 U/kg/min (N=30) n (%); m 50% Reduced Volume; Increased Rate 10 U/kg/min (N=28) n (%); m Overall 50% Reduced Volume Includes the following infusion rates: 2 U/kg/min; 4 U/kg/min and 10 U/kg/min (N=30) n (%); m n=Number of subjects, m=number of events Adverse reactions (ARs) Nervous system disorders Headache 0 0 2 (6.7%); 2 Infusion related AEs Nervous system disorders Headache 0 0 2 (6.7%); 2 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of FEIBA.
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.
Blood and Lymphatic System Disorders: disseminated intravascular coagulation Cardiac Disorders: tachycardia, flushing Respiratory, Thoracic, and Mediastinal Disorders: bronchospasm, wheezing Gastrointestinal Disorders: abdominal discomfort Skin and Subcutaneous Tissue Disorders: pruritus General Disorders and Administration Site Conditions: malaise, feeling hot, injection site pain Investigations: Fibrin D-dimer increased
The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
The most common adverse reactions observed in >5% of subjects were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting.
( 6.1 ) The serious adverse drug reactions are hypersensitivity and thromboembolic events, including stroke, pulmonary embolism, and deep vein thrombosis.
( 5.1 , 5.2 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc.
at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety assessment of FEIBA is based on the review of the data from two prospective clinical trials in which FEIBA was used for the treatment of acute bleeding episodes and a prospective trial that compared the use of FEIBA prophylactically versus on-demand treatment.
The adverse reactions reported from two prospective clinical trials in which FEIBA was used for the treatment of acute bleeding episodes were chills, chest pain, chest discomfort, dizziness, dysgeusia, dyspnea, hypoesthesia, increase of inhibitor titer (anamnestic response), nausea, pyrexia, and somnolence.
Specifically, the first trial was a multicenter randomized, double-blind trial in 15 hemophilia A subjects with inhibitors to factors VIII.
The second trial was a multicenter FEIBA study conducted in 44 hemophilia A subjects with inhibitors, 3 hemophilia B subjects with inhibitors and 2 acquired factor VIII inhibitor subjects.
Of the 489 infusions used to treat acute bleeds during the second trial, 18 (3.7%) caused minor transient reactions of chills, fever, nausea, dizziness and dysgeusia.
Out of 49 subjects, 10 (20%) had a rise in their inhibitor titers after treatment with FEIBA.
Five of these subjects (50%) had increases that were tenfold or more, and 3 (30%) of these subjects received factor VIII or IX concentrates within 2 weeks prior to treatment with FEIBA.
These anamnestic rises were not associated with decreased efficacy of FEIBA.
Table 2 lists the adverse reactions in >5% of subjects reported in the randomized, prospective prophylaxis trial comparing FEIBA prophylaxis with on-demand treatment in 36 hemophilia A and B subjects with inhibitors to factors VIII or IX 3 .
The trial population included 33 (92%) subjects with hemophilia A and 3 (8.3%) subjects with hemophilia B.
Four (11%) subjects were ≥7 to <12 years of age, 5 (14%) were ≥12 to <16 years of age, and 27 (75%) were ≥16 years of age.
A total of 29 (80.6%) subjects were Caucasian, 3 (8.3%) Asian, 2 (5.6%) Black/African American, and 2 (5.6%) other.
The subjects received a total of 4,513 infusions (3,131 for prophylaxis and 1,382 for on-demand).
Table 2: Prophylaxis Study Adverse Reactions (ARs) in >5% of Subjects MedDRA System Organ Class Adverse Reaction Number of ARs Number of Subjects Percent of Subjects (N=36) Blood And Lymphatic System Disorders Anemia 2 2 5.6 Gastrointestinal Disorders Diarrhea 2 2 5.6 Nausea 2 2 5.6 Vomiting 2 2 5.6 Investigations Hepatitis B Surface Antibody Positive 4 4 11.1 Musculoskeletal And Connective Tissue Disorders Hemarthrosis 5 3 8.3 Table 3 lists the adverse reactions and infusion related adverse events reported in >5% of subjects in any of the three groups (50% Reduced Volume, Increased Rate 4 U/kg/min; 50% Reduced Volume, Increased Rate 10 U/kg/min; Overall 50% Reduced Volume) of the randomized, prospective crossover trial evaluating the tolerability and safety of infusing reduced volume of FEIBA at the standard infusion rate of 2 U/kg/min, and at increased rates of 4 and 10 U/kg/min in a total of 33 treated subjects with congenital Hemophilia A with inhibitors.
Table 3: Adverse Reactions (ARs) and Infusion Related Adverse Events in >5% of Subjects, in Patients 18 Years and Older MedDRA System Organ Class Adverse Reaction 50% Reduced Volume; Increased Rate 4 U/kg/min (N=30) n (%); m 50% Reduced Volume; Increased Rate 10 U/kg/min (N=28) n (%); m Overall 50% Reduced Volume Includes the following infusion rates: 2 U/kg/min; 4 U/kg/min and 10 U/kg/min (N=30) n (%); m n=Number of subjects, m=number of events Adverse reactions (ARs) Nervous system disorders Headache 0 0 2 (6.7%); 2 Infusion related AEs Nervous system disorders Headache 0 0 2 (6.7%); 2 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of FEIBA.
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.
Blood and Lymphatic System Disorders: disseminated intravascular coagulation Cardiac Disorders: tachycardia, flushing Respiratory, Thoracic, and Mediastinal Disorders: bronchospasm, wheezing Gastrointestinal Disorders: abdominal discomfort Skin and Subcutaneous Tissue Disorders: pruritus General Disorders and Administration Site Conditions: malaise, feeling hot, injection site pain Investigations: Fibrin D-dimer increased